AdipoGen Life Sciences

Staurosporine

CHF 30.00
In stock
AG-CN2-0022-C100100 µgCHF 30.00
AG-CN2-0022-C500500 µgCHF 40.00
AG-CN2-0022-M0011 mgCHF 75.00
AG-CN2-0022-M0055 mgCHF 190.00
More Information
Product Details
Synonyms Antibiotic AM2282; Antibiotic 230; CCRIS 3272
Product Type Chemical
Properties
Formula C28H26N4O3
MW 466.5
Merck Index 14:8802
CAS 62996-74-1
RTECS KC655000
Source/Host Chemicals Isolated from Streptomyces spiralis.
Purity Chemicals ≥98% (HPLC)
Appearance Off-white to yellow solid.
Solubility Soluble in DMSO, ethyl acetate or dimethyl formamide. Insoluble in water.
InChi Key HKSZLNNOFSGOKW-FYTWVXJKSA-N
Smiles [H][C@]12C[C@@H](NC)[C@@H](OC)[C@](C)(O1)N1C3=C(C=CC=C3)C3=C4CNC(=O)C4=C4C5=C(C=CC=C5)N2C4=C13
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Protect from moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • Antibiotic.
  • Antifungal and anti-yeast activity [1].
  • Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation [2].
  • Potent, cell permeable, reversible, ATP-competitive and broad spectrum inhibitor of protein kinases. Inhibits protein kinase A (PKA), CaM kinase, myosin light chain kinase, protein kinase C (PKC), protein kinase G, CDK1/cyclin B, CDK2/cyclin A, CDK4/cyclin D, CDK5/p25, GSK-3β and Pim-1 kinase [3, 4, 5, 6, 12].
  • DYRK1A inhibitor (IC50=20nM) [13].
  • Key apoptosis inducer [7, 8, 10, 11].
  • Topoisomerase II (Topo II) inhibitor [9].
Product References
  1. A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization: S. Omura, et al.; J. Antibiot. (Tokyo) 30, 275 (1977)
  2. Staurosporine, a potent platelet aggregation inhibitor from a Streptomyces species: S. Oka, et al.; Agric. Biol. Chem. 50, 2723 (1986)
  3. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase: T. Tamaoki, et al.; BBRC 135, 397 (1986)
  4. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60: N. Nakano, et al.; J. Antibiot. (Tokyo) 40, 706 (1987)
  5. Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases: U.T. Ruegg & G.M. Burgess; TIPS 10, 218 (1989) (Review)
  6. Staurosporine: an effective inhibitor for Ca2+/calmodulin-dependent protein kinase II: N. Yanagihara, et al.; J. Neurochem. 56, 294 (1991)
  7. Induction of a common pathway of apoptosis by staurosporine: R. Bertrand, et al.; Exp. Cell Res. 211, 314 (1994)
  8. Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway: D.A. Wiesner & G. Dawson; J. Neurochem. 66, 1418 (1996)
  9. Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors: P. Lassota et al.; J. Biol. Chem. 271, 26418 (1996)
  10. Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines: J. Boix, et al.; Neuropharmacology 36, 811 (1997)
  11. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts: H.J. Chae, et al.; Pharmacol. Res. 42, 373 (2000)
  12. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002: M.D. Jacobs, et al.; J. Biol. Chem. 280, 13728 (2005)
  13. Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles: C. Sanchez, et al.; Chem. Commun. 2009, 4118 (2009)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.